Le Lézard
Classified in: Health, Sports and recreation
Subjects: WOM, FVT, DEI

EverGlade Funding Alert - $100 Million Funding Opportunity Announced for ARPA-H Sprint for Women's Health Initiative


By Merissa Mayo, Senior Consultant and Eric Jia-Sobota, Founder

HOUSTON, March 6, 2024 /PRNewswire/ -- The Advanced Research Projects Agency for Health (ARPA-H) announced the launch of the Sprint for Women's Health initiative aimed at revolutionizing women's health. The Sprint for Women's Health new request for solutions (RFS) seeks proposals from innovators, researchers, and entrepreneurs to address critical challenges and disparities in women's health.

"The Sprint for Women's Health initiative is a crucial step towards addressing the complex and multifaceted challenges that women face in healthcare. By focusing on innovation and inclusivity, this initiative has the potential to transform women's health outcomes for the better," stated EverGlade Senior Consultant, Merissa Mayo.

Sprint for Women's Health offers two distinct funding tracks to support innovative research and development efforts. These two tracks are distinguished by the solution's level of technology readiness: "Spark" solutions foster early-stage research while "Launchpad" solutions focus on later-stage development. Both tracks are open for all six women's health topics identified by ARPA-H.

"The Sprint for Women's Health RFS demonstrates ARPA-H's commitment to improving women's health outcomes. By focusing on both early-stage research and later-stage development, this initiative has the potential to accelerate the translation of research into impactful solutions," stated EverGlade Consulting Founder, Eric Jia-Sobota.

The submission process for the Sprint for Women's Health RFS program is streamlined, requiring a Solution Summary followed by a pitch session. The Solution Summary is a three-page document that outlines how the proposed idea aligns with ARPA-H's mission and the specified women's health topic areas. Submissions are due April 12, 2024.

Selected participants in the Sprint for Women's Health RFS program will work directly with an ARPA-H Program Manager (PM) and receive an ARPA-H award contracted through the ARPANET-H Investor Catalyst Hub. The expected period of performance for the funding opportunity tracks is 18-24 months.

If your company has considered applying for ARPA-H funding, your federal funding journey starts here. EverGlade Consulting is a national consulting firm connecting public sector needs with private sector solutions. We offer services ranging from Pursuit, Proposal and Post-Award support to comply with federal regulations at agencies including BARDA, ASPR, NIH, DTRA, JPEO, DOD, DIU, DOE, and DARPA.

For additional information about EverGlade Consulting, reach out to:

[email protected]

SOURCE EverGlade Consulting


These press releases may also interest you

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

18 mai 2024
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: